Navigation Links
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support

VIENNA, Austria, May 27 /PRNewswire/ -- The atherosclerosis vaccine development program by AFFiRiS AG is receiving financial support from the EU's EUROTRANS-BIO call. The respective project is being carried out in cooperation with German company EMC microcollections GmbH. The aim of atherosclerosis vaccination is to increase the amount of "good" high density lipoprotein cholesterol (HDLc) in the blood and thus reduce the occurrence of harmful fatty deposits in the arteries. Product candidates were delivered by AFFiRiS' AFFITOME(R) platform technology. The target is a protein known as CETP (cholesteryl ester transfer protein). Following vaccines for Alzheimer's disease and Parkinson's disease, the atherosclerosis vaccine is the third such project announced by AFFiRiS AG.

Vienna-based AFFiRiS AG today announced that its atherosclerosis vaccine development program is receiving support from the EU's EUROTRANS-BIO call. The supported project - known as CETP Vaccine (ETB-2008-28) - is based on the AFFITOME(R) technology of AFFiRiS AG and is being conducted together with EMC microcollections GmbH from Tubingen, Germany. The urgent need for an effective strategy against atherosclerosis is clearly evident from the relevant figures - diseases of the cardiovascular system are the number one cause of death in Europe and the US. In Europe, this is at the root of almost 50 % of all deaths. One of the primary causes of cardiovascular disease is atherosclerosis, a narrowing of key arteries due to fatty deposits. Although there are options for medication-based intervention in the form of statins, these are deemed to be of limited effectiveness despite some notable successes.

CSO Dr. Frank Mattner explains: "Today's therapies with Statins act on low density lipoprotein cholesterol (LDLc) and reduce its concentration in the blood. This type of treatment can reduce the likelihood of severe heart disease by as little as 30 % - and that's only if the patient takes the necessary medication correctly and regularly. In contrast, our vaccine approach aims at decreasing the cholesterol transfer from HDL to LDL, thus increasing the concentration of the beneficial HDL. This vaccine approach with its long-lasting effects should avoid patients having to take life-long, daily medication to a strict regimen."

The main item of the joint efforts of AFFiRiS and EMC is the vaccination against cholesteryl ester transfer protein (CETP). By transferring cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces "good" HDL and has a detrimental impact on the ratio of LDLc to HDLc. In the future, our vaccine will reduce the activity of this protein and shift the balance of HDLc and LDLc in the blood back in favour of HDLc.

Outlining the major benefit of the AFFITOME(R) technology, project manager Dr. Sylvia Brunner adds: "CETP is one of the body's own proteins. Trying to reduce its activity using a vaccine, we are faced with a formidable challenge. The body has many means of suppressing an immune response to its own proteins, or limiting the effectiveness of any such response. That's why previous attempts to develop a vaccine against CETP failed. However, as AFFiRiS has already demonstrated in its work on a vaccine for Alzheimer's disease, the AFFITOME(R) technology makes it possible to circumvent these mechanisms. We are now applying this principle to atherosclerosis."

CEO Dr. Walter Schmidt continues: "So far, we have announced the development of vaccines for three diseases - Alzheimer's, Parkinson's and now atherosclerosis. Currently, four other indications are also part of our development pipeline, all of them characterised by a very high number of patients but also by a lack of satisfactory treatments. As a result, these indications fit in well with our long-term strategy. Our strategy itself is beginning to pay back as demonstrated by the licensing agreement worth EUR 430 million that we recently concluded with GSK Biologicals regarding the rights for the technology for our Alzheimer's vaccine programs."

The CETP Vaccine project is scheduled to last 30 months and is due to culminate in phase I clinical trials. Overall, the support provided to the project by the EU is worth several hundred thousand euros, while the two project partners are bearing around half of the total costs.

About AFFiRiS AG (as at May 2009):

AFFiRiS AG develops customised peptide-based vaccines based on its own patents. These are used to treat Alzheimer's disease, atherosclerosis, Parkinson's disease and other diseases that urgently require a medical solution and for which the market volumes are highly attractive. Alzheimer's disease is currently the foremost indication and two potential products are in the final stages of clinical phase I studies. In October 2008, the company succeeded in gaining GlaxoSmithKline Biologicals as its licensing partner for the Alzheimer's vaccine. The contract foresees payments of up to EUR 430 million (these payments are dependent on certain milestones). AFFiRiS currently employs 50 highly-qualified staff and recently acquired an additional 1,100 square meters of premises at the St. Marx campus in Vienna, Austria (

    Contact at AFFiRiS AG:
    Agnes Meyer
    Karl-Farkas-Gasse 22
    1030 Vienna
    T +43-1-798-15-75-390

    Copy Editing & Distribution:
    PR&D - Public Relations for Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    T +43-1-505-70-44

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
3. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
4. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
5. Old and new therapies combine to tackle atherosclerosis
6. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
7. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
8. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
10. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
11. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Post Your Comments:
(Date:11/30/2015)... 1, 2015  An interventional radiology technique shows promise for ... results of a study being presented today at the annual ... (RSNA). --> ... by interventional radiologists as a way to stop bleeding in ... a means of treating obesity is new. Mubin ...
(Date:11/30/2015)... includes an MPP licen ... niversity , s Solid Drug Nanoparticle (SDN) Technology ; ... up through cost cuts of priority ... based anywhere in the world will have the right to make, use and distribute ... where licensees based anywhere in the world will have the right to make, use ...
(Date:11/30/2015)... 2015 Harvard Apparatus Regenerative Technology, Inc. ... developing bioengineered organ implants for life-threatening conditions, today ... NASDAQ Stock Market that it has regained compliance ... noted that as a result of the closing ... $1.00 per share for more than ten consecutive ...
(Date:11/30/2015)... Md. , Nov. 30, 2015 ... development company committed to the fostering and monetization ... the current and prospective initiatives designed to create ... Chief Executive Officer of Spherix. "Based on published ... future licensees exceeds $50 billion and Spherix will ...
Breaking Biology Technology:
(Date:11/19/2015)... VIEW, Calif. , Nov. 19, 2015  Based ... market, Frost & Sullivan recognizes BIO-key with the 2015 ... Leadership. Each year, Frost & Sullivan presents this award ... product line catering to the needs of the market ... the product line meets and expands on customer base ...
(Date:11/17/2015)... , November 17, 2015 Paris ... 2015.   --> Paris from 17 ... DERMALOG, the biometrics innovation leader, has invented the first ... fingerprints on the same scanning surface. Until now two different ... Now one scanner can capture both on the same ...
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
Breaking Biology News(10 mins):